Gotoh A - Search Results

1

Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.

Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Gotoh A, et al. J Urol. 1998 Jul;160(1):220-9. J Urol. 1998. PMID: 9628654

2

Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.

Shirakawa T, Gotoh A, Zhang Z, Kao C, Chung LW, Gardner TA. Shirakawa T, et al. Among authors: gotoh a. Urology. 2004 Mar;63(3):613-8. doi: 10.1016/j.urology.2003.09.054. Urology. 2004. PMID: 15028478

3

Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo.

Shigemura K, Shirakawa T, Wada Y, Kamidono S, Fujisawa M, Gotoh A. Shigemura K, et al. Among authors: gotoh a. Urology. 2005 Dec;66(6):1239-44. doi: 10.1016/j.urology.2005.06.076. Urology. 2005. PMID: 16360450

4

[Clinical application for gene therapy in prostate cancer].

Gotoh A, Kamidono S, Chung LW. Gotoh A, et al. Hinyokika Kiyo. 1997 Nov;43(11):829-33. Hinyokika Kiyo. 1997. PMID: 9436031 Free article. Japanese.

5

In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.

Shirakawa T, Ko SC, Gardner TA, Cheon J, Miyamoto T, Gotoh A, Chung LW, Kao C. Shirakawa T, et al. Among authors: gotoh a. Cancer Gene Ther. 1998 Sep-Oct;5(5):274-80. Cancer Gene Ther. 1998. PMID: 9824046

6

Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model.

Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LW, Kao C. Shirakawa T, et al. Among authors: gotoh a. J Urol. 1999 Sep;162(3 Pt 1):949-54. doi: 10.1097/00005392-199909010-00096. J Urol. 1999. PMID: 10458414

7

Gene therapy for bladder cancer using adenoviral vector.

Wada Y, Gotoh A, Shirakawa T, Hamada K, Kamidono S. Wada Y, et al. Among authors: gotoh a. Mol Urol. 2001 Summer;5(2):47-52. doi: 10.1089/109153601300177547. Mol Urol. 2001. PMID: 11690547

8

Tissue-specific promoters in gene therapy for the treatment of prostate cancer.

Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW. Shirakawa T, et al. Among authors: gotoh a. Mol Urol. 2000 Summer;4(2):73-82. doi: 10.1089/10915360050138620. Mol Urol. 2000. PMID: 12006246 Review.

9

Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.

Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LW. Ko SC, et al. Among authors: gotoh a. Cancer Res. 1996 Oct 15;56(20):4614-9. Cancer Res. 1996. PMID: 8840973

10

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.

Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW. Ko SC, et al. Among authors: gotoh a. Hum Gene Ther. 1996 Sep 10;7(14):1683-91. doi: 10.1089/hum.1996.7.14-1683. Hum Gene Ther. 1996. PMID: 8886839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

455 results

Search Page

Filters